Table 2. Novel SNPs identified in a multi-stage GWAS of bladder cancer.

Results of the meta-analysis of genotype counts included in combined stages I, II and III. The initial scan results were adjusted by age, gender, smoking status, study site and DNA source.

Markera, minor alleleb, chrc, locationc and gened	Studies included	Ne	Cases	Controls	Freq.f	Allelic OR (95%CI)g			P valueh
rs1014971 [C ]	Stage I	5	3,529	5,092	0.38	0.87	0.82	0.93	6.1E-05
Chr 22q13.1:	Stage II and III	15	8,277	47,517	0.37	0.89	0.85	0.93	3.0E-08
37662569	Combined	20	11,806	52,609	0.38	0.88	0.85	0.91	8.4E-12
CBX6, APOBEC3A
rs8102137 [C]	Stage I	5	3,530	5,114	0.33	1.13	1.06	1.21	1.6E-04
Chr 19q12:	Stage II and III	15	8,261	47,708	0.32	1.13	1.08	1.18	2.6E-08
34988693	Combined	20	11,791	52,822	0.33	1.13	1.09	1.17	1.7E-11
CCNE1
rs11892031 [C]	Stage I	5	3,524	5,108	0.08	0.79	0.70	0.89	6.9E-05
Chr 2q37.1:	Stage II and III	15	8,284	47,727	0.08	0.86	0.80	0.93	1.8E-04
234230022	Combined	20	11,808	52,835	0.08	0.84	0.79	0.89	1.0E-07
UGT1A cluster j
rs1495741 [G]	Stage I	5	3525	5116	0.24	0.86	0.80	0.93	1.5E-04
Chr 8p22:	Stage II and III	15	8,279	47,744	0.22	0.87	0.83	0.92	6.8E-08
18317161	Combined	20	11,804	52,860	0.24	0.87	0.83	0.91	4.2E-11
NAT2

^aNCBI dbSNP identifier.

^bMinor allele shown in [].

^cChromosome and NCBI Human Genome Build 36.3 location.

^dGene neighborhood closest to the most notable SNP.

^eN: number of studies

^fMinor allele frequency in control populations.

^gEstimate assuming multiplicative odds model, OR, odds ratio; CI, 95% confidence interval.

^h1 d.f. trend test.